Jaya White Comments on Possible Impact of FTC’s New Premerger Rules in Lab Industry Advisor Article
Jaya White, national co-chair of the Quarles & Brady Long-Term Care and Clinical Laboratories practices, was quoted in a Lab Industry Advisor article about the impact new federal premerger regulations could have on dealmaking in the health care industry.
The U.S. Federal Trade Commission (FTC) in October approved the changes to premerger rules under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The new rules, which go into effect in January, address the forms that must be submitted to the FTC by the entities involved in a proposed merger and acquisition.
White said the new rules could slow the pace of deals. An excerpt:
Jaya White, a Chicago-based partner in the health and life sciences practice group at Quarles & Brady, believes the new rules could chill some dealmaking.
“We anticipate…that it will slow down the overall deal timeline, and reduce the number or size of the transactions,” White said in an email.
White noted that in addition to the new rules at the federal level, many states are also expanding the scope of information they are seeking for such deals as well.
“It remains to be seen what changes will happen at the state level with a new [presidential] administration, though at this time, we continue to see an increase in these types of laws across the states,” White said.